Indirect laser treatment and anti-vegf therapy of a retinal angioma, with resolution of a large serous retinal detachment, Mmacular exudates, and macular edema

Seminars in Ophthalmology

Volumn 25, Issue 1-2, 2010, Pages 21-26

  Rarey, Kristin ^a   Friberg, Thomas R ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Indirect laser treatment

Indexed keywords

BEVACIZUMAB; PEGAPTANIB; VASCULOTROPIN INHIBITOR;

AGED; ANGIOMA; ARGON LASER; ARTICLE; B SCAN; BLURRED VISION; CASE REPORT; EYE EXAMINATION; EYE INJURY; FEMALE; HUMAN; IMAGE ANALYSIS; IMAGE DISPLAY; LASER COAGULATION; LOW LEVEL LASER THERAPY; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; RETINA DETACHMENT; RETINA EXUDATE; RETINA FLUORESCEIN ANGIOGRAPHY; RETINA MACULA CYSTOID EDEMA; RETINAL ANGIOMA; SLIT LAMP; TREATMENT DURATION; TREATMENT RESPONSE; VISUAL ACUITY;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; APTAMERS, NUCLEOTIDE; COMBINED MODALITY THERAPY; EXUDATES AND TRANSUDATES; FEMALE; FLUORESCEIN ANGIOGRAPHY; HEMANGIOMA; HUMANS; LASER COAGULATION; MACULAR EDEMA; RETINAL DETACHMENT; RETINAL NEOPLASMS; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 77952919271     PISSN: 08820538     EISSN: 17445205     Source Type: Journal    
DOI: 10.3109/08820538.2010.481246     Document Type: Article

References (10)

1. Aiello LP, George DJ, Cahill MT, Wong JS, Cavallerano J, Hannah AL, Kaelin WG Jr. Rapid and durable recovery of visual function in a patient with von Hippel-Lindau syndrome after systemic therapy with vascular endothelial growth factor receptor inhibitor su5416. Ophthalmology. 2002 Sep; 109(9):1745-1751.
2. Aumiller MS. Juxtapapillary hemangioma: a case report and review of clinical features and management of von Hippel-Lindau disease. Optometry. 2005 Aug; 76(8):442-449.
3. Dahr SS, Cusick M, Rodriguez-Coleman H, Srivastava SK, Thompson DJ, Linehan WM, Ferris FL 3rd, Chew EY. Intravitreal anti-vascular endothelial growth factor therapy with pegaptanib for advanced von Hippel-Lindau disease of the retina. Retina. 2007 Feb; 27(2):150-158.
4. Friberg TR. Clinical experience with a binocular indirect ophthalmoscope laser delivery system. Retina. 1987; 7:28-32.
5. Girmens JF, Erginay A, Massin P, Scigalla P, Gaudric A, Richard S. Treatment of von Hippel-Lindau retinal hemangioblastoma by the vascular endothelial growth factor receptor inhibitor SU5416 is more effective for associated macular edema than for hemangioblastomas. Americal Journal of Ophthalmology. 2003 July; 194-196.
6. Palmer JD, Gragoudas ES. Advances in treatment of retinal angiomas. Int Ophthalmol Clin. 1997 Fall; 37(4): 159-170.
7. Wittebol-Post D, Hes FJ, Lips CJ.The eye in von Hippel-Lindau disease. Long-term follow-up of screening and treatment: recommendations. J Intern Med. 1998 Jun; 243(6):555-561.
8. Wittenberg L, Ma P. Treatment of a von Hippel-Lindau retinal capillary hemangioma with photodynamic therapy. Canadian Journal of Ophthalmology. 2008; 43: 605-606.
9. Wong W, Yeh S, Chan CC, Kalina R, Kinyoun JL, Folk JC, Coleman H, Chew E. Retinal vascular proliferation as an ocular manifestation of von Hippel-Lindau Disease. Arch Ophthalmol. 2008 May; 126:637-643. (Pubitemid 351679558)
10. Wong W, Chew E. Ocular von Hippel-Lindau disease: clinical update and emerging treatments. Curr Opin Ophthalmol. 2008; 19:213-217. (Pubitemid 351535917)